Summary: | Breast cancer is one of the most common and malignant cancers nowadays. Like many
cancers, it is extensively regulated by pro-angiogenic and pro-lymphangiogenic factors, which
induce rapid vasculature growth. This results in aberrant vessels which enhance a pro-tumor
environment by preventing treatment against cancer to get to the tumor, inducing the
malignancy of cancer cells, and inhibiting the immune response. In the last years, antiangiogenic
treatment was suggested as a possible way to eliminate the tumor-supporting
environment. This approach was soon replaced by the judicious use of these anti-angiogenic
molecules in normalizing concentrations, to prevent pro-tumor effects, such as cell
malignification. In a novel approach to prevent these processes to occur, we have designed a
treatment based on the normalization of the tumoral vasculature of triple-negative breast
carcinoma, so they return to their physiological state. For this aim, we have analyzed the
effects of the blockage of VEGF-A and VEGF-C signaling pathways (angiogenesis and
lymphangiogenesis), by targeting their receptors, VEGFR2 and VEGFR3, with inhibitor
molecules (DC101 antibody and SAR131675 molecules).
|